Evidence map›Paper›PMID 27883280›Full record

ArticleThoracic cancer2017

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

Minoru Fukuda, Midori Shimada, Takeshi Kitazaki, Seiji Nagashima, Kohji Hashiguchi, Noriyuki Ebi, Koichi Takayama, Yoichi Nakanishi, Hiroshi Semba, Taishi Harada and 4 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Minoru FukudaClinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Midori ShimadaDivision of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Takeshi KitazakiDivision of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Seiji NagashimaDepartment of Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
Kohji HashiguchiDivision of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Noriyuki EbiDepartment of Respiratory Oncology Medicine, Iizuka Hospital, Fukuoka, Japan.
Koichi TakayamaDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoichi NakanishiResearch Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.
Hiroshi SembaDepartment of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan.
Taishi HaradaResearch Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.
Takashi SetoDepartment of Thoracic Oncology, National Kyusyu Cancer Center, Fukuoka, Japan.
Isamu OkamotoResearch Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.
Yukito IchinoseClinical Research Institute, National Kyusyu Cancer Center, Fukuoka, Japan.
Kenji SugioDepartment of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
Japanese Red Cross Society, Japan · JPKyushu University · JPNational Hospital Organization Kyushu Cancer Center · JPAso Iizuka Hospital · JPKumamoto Medical Center · JPKyoto Prefectural University of Medicine · JPNagasaki Medical Center · JPNagasaki University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVarious polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism.

methodsThe eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /- and *6 /-), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function. The patients were scheduled to receive irinotecan on days 1, 8, 15, 22, 29, and 36.

resultsFour patients were enrolled in this trial. Two patients were determined to be ineligible. The remaining two patients, who belonged to group B, received an initial irinotecan dose of 60 mg/m

conclusionsThe MTD of irinotecan for previously treated lung cancer patients that are heterozygous for the UGT1A1 * 28 or UGT1A1 * 6 gene polymorphism is 60 mg/m

Indexed as

Antineoplastic Agents, PhytogenicCamptothecinGlucuronosyltransferaseLung NeoplasmsPolymorphism, Single NucleotideAgedDrug Administration ScheduleFemaleHumansIrinotecanMaleMaximum Tolerated DoseMiddle AgedTreatment OutcomeUGT1A1 EnzymeAntineoplastic Agents, PhytogenicCamptothecinGlucuronosyltransferaseIrinotecanUGT1A1 EnzymeGene polymorphismirinotecanlung cancerphase IUGT1A 1

Identifiers

PMID27883280
PMCPMC5217920
OpenAlexW2552528469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.